Welcome to our dedicated page for Immunoprecise SEC filings (Ticker: IPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), files as a foreign private issuer and its SEC reports document operating results, platform development, capital structure, governance matters, and risk disclosures. Form 6-K reports furnish earnings releases and business updates for the Bio-Native AI drug-discovery business, including LensAI™, HYFT® technology, biologics services, B Cell Llama™ nanobody discovery, immunogenicity screening, and vaccine-target research.
The filing record also captures corporate-status changes tied to the MindWalk rebrand and Nasdaq ticker change, along with disclosures on issued capital, share-based awards, lease obligations, development costs, segment information, material agreements, and historical financial condition. These documents frame the company's transition from specialized wet-lab antibody services toward an integrated AI and laboratory platform model.
ImmunoPrecise Antibodies filed a Form 6-K (foreign issuer report) on June 28, 2025, indicating the submission of a press release dated June 24, 2025. The filing was signed by Jennifer Bath, who serves as President and Chief Executive Officer.
The company confirms it will file annual reports under Form 20-F rather than Form 40-F. The principal executive office is located in Austin, Texas.
Note: While this is a Form 6-K filing, the actual content and details of the press release (Exhibit 99.1) are not included in this portion of the filing. The Form 6-K serves primarily as a cover document for the attached press release, which would contain the material information being reported to shareholders.